跳至主要内容
临床试验/NCT01258309
NCT01258309已完成3 期

Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis

Allergan0 个研究点目标入组 129 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
129
主要终点
Ocular Itching

研究概览

简要总结

This study will investigate the safety and efficacy of olopatadine hydrochloride / ketorolac tromethamine fixed dose combination ophthalmic solution compared with olopatadine hydrochloride ophthalmic solution in patients with seasonal allergic conjunctivitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of seasonal allergic conjunctivitis

排除标准

  • Ocular infection or history of ocular herpes infection
  • History of retinal detachment or diabetic retinopathy
  • Prior or current use of systemic or topical steroids, NSAIDs, anticholinergics, immunosuppressants, or antihistamines
  • Ocular surgery within 8 weeks

研究组 & 干预措施

1

Experimental

olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution

干预措施: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution (Drug)

2

Active Comparator

olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution

干预措施: olopatadine hydrochloride 0.1% ophthalmic solution (Drug)

结局指标

主要结局

Ocular Itching

时间窗: Day 21

次要结局

  • Chemosis(Day 21)
  • Hyperemia(Day 21)
  • Ocular mucous discharge(Day 21)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验